Recent events
Recent events tied to this brand in public sources.
Back to profile12 entries
2022
Agilent acquires ACIES technology
Agilent Technologies acquired AI technology developed by Virtual Control, including the intellectual property and other assets associated with ACIES, and said it would integrate the technology into its lab informatics platforms.
2022
Agilent acquires ACIES technology and assets
Agilent announced that it acquired AI technology developed by Virtual Control, including the ACIES software and associated assets, and said it would integrate the technology into its laboratory platforms and MassHunter software package.
2021
Oxford BioDynamics and Agilent signed a supply and resale agreement
Oxford BioDynamics and Agilent Technologies signed a supply and resale agreement for manufacturing and selling the EpiSwitch Explorer Array Kit. Agilent will supply a custom-made microarray, and Oxford BioDynamics has exclusive supply and distribution rights for the kit.
2021
Agilent announces acquisition of Resolution Bioscience
Agilent Technologies agreed to acquire liquid-biopsy company Resolution Bioscience for $550 million in upfront cash, with up to $145 million in additional payments tied to future performance milestones. The transaction was expected to close in April 2021.
2021
FDA approves Agilent assay for use as a companion diagnostic
The FDA approved Agilent Technologies' PD-L1 IHC 22C3 pharmDx assay for expanded use in non-small cell lung cancer, including as a companion diagnostic for first-line cemiplimab monotherapy in eligible patients with advanced disease.
2020
Agilent announces NanoDis System
Agilent Technologies announced the introduction of the NanoDis System for nanoparticle dissolution testing.
2020
Biofidelity completes $12 million Series A financing
Biofidelity announced the successful completion of a $12 million Series A financing, led by BlueYard Capital and backed by other investors, including Longwall Ventures and Agilent Technologies.
2020
FDA approves expanded use of Agilent PD-L1 assay
The U.S. Food and Drug Administration approved Agilent’s PD-L1 IHC 28-8 pharmDx for expanded use in non-small cell lung cancer, including as an aid in identifying patients with metastatic disease for treatment with Opdivo and Yervoy.
2020
Agilent introduces Vaya Raman verification system
Agilent Technologies announced the launch of the Vaya Raman raw material identity verification system, a handheld instrument designed for pharmaceutical and biopharmaceutical quality-control testing.
2020
Agilent introduces SureSelect XT HS2 DNA Kit
Agilent introduced the SureSelect XT HS2 DNA Kit, a product designed to address challenges laboratories encounter when preparing DNA sequencing libraries for research.
2019
Akoya Biosciences completes $50 million financing
Akoya Biosciences announced the completion of a $50 million financing from new and existing investors. The financing will support commercial and operational expansion and continued development of its CODEX and Phenoptics platforms.
2019
Burning Rock and Agilent launch Magnis BR
Burning Rock and Agilent held a launch event for Magnis BR, an automated NGS library-preparation system they jointly developed, and announced the start of its market promotion in China.